WEBULL
News
DVAX
15.50
0.00%
0.00
Dynavax Completes Merger and Prepares Nasdaq Delisting
TipRanks · 2d ago
Sanofi Completes Acquisition of Dynavax Technologies
Reuters · 2d ago
NASDAQ TRADE HALT <DVAX.O> TRADING HALTED; FOR INFORMATION REQUESTED BY NASDAQ AT 07:50 PM
Reuters · 2d ago
Weekly Report: what happened at DVAX last week (0202-0206)?
Weekly Report · 3d ago
BUZZ-OneSpaWorld jumps as co poised to join S&P SmallCap index
Reuters · 02/05 14:28
OneSpaWorld Holdings Will Replace Dynavax Technologies In The S&P SmallCap 600 Effective Prior To The Opening Of Trading On February 10,2026
Benzinga · 02/04 22:27
OneSpaWorld to replace Dynavax in S&P 600 at open on 2/10
TipRanks · 02/04 22:25
Assessing Dynavax Technologies (DVAX) Valuation After Recent Share Price Momentum And Ongoing Pipeline Investment
Simply Wall St · 02/03 10:18
Weekly Report: what happened at DVAX last week (0126-0130)?
Weekly Report · 02/02 09:10
Is Dynavax Technologies (DVAX) Pricing Reflect Its Biotech Role And Recent Share Performance
Simply Wall St · 02/01 23:17
Sanofi Buyout Of Dynavax Recasts Adult Vaccine Growth For Shareholders
Simply Wall St · 01/31 21:45
Weekly Report: what happened at DVAX last week (0119-0123)?
Weekly Report · 01/26 09:10
Weekly Report: what happened at DVAX last week (0112-0116)?
Weekly Report · 01/19 09:11
Ocular surges on report of Sanofi buyout bid
Seeking Alpha · 01/15 13:02
Is Dynavax Technologies (DVAX) Pricing Reflect Its Recent Rally And DCF Implied Upside Potential
Simply Wall St · 01/14 11:24
Dynavax Received, Rejected Buyout Offer From Undisclosed Bidder
Dow Jones · 01/12 20:10
*Dynavax: 'Party A' CEO Sent a Non-Binding $15/Shr Proposal on Dec. 23
Dow Jones · 01/12 19:24
*Dynavax Files Tender Offer Recommendation Statement Related to Sanofi Deal, Mentions Talks With 'Party A'
Dow Jones · 01/12 19:22
Dynavax gains on disclosure another bidder interested after deal announced
Seeking Alpha · 01/12 16:13
Weekly Report: what happened at DVAX last week (0105-0109)?
Weekly Report · 01/12 09:11
More
Webull provides a variety of real-time DVAX stock news. You can receive the latest news about Dynavax Technolo through multiple platforms. This information may help you make smarter investment decisions.
About DVAX
Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.